This week, we have conversations with Jakob Andersson, vice president of engineering at Anaphora and founder and chairman of GAIA; Coave Therapeutics’ CEO Rodolphe Clerval; and MOBILion Systems’ CEO, Melissa Sherman.

Times:

03:13 Coave Therapeutics

24:43 GAIA Conference

36:55 MOBILion Systems

Genetic medicine for ophthalmology

Coave Therapeutics is a Paris‑based biotechnology company focused on developing genetic medicines using its ALIGATER platform. The company has pioneered ligand‑conjugated AAV vectors, enabling precision capsids that are highly tissue‑specific, safer, and more effective.

In October 2025, Coave presented data at the European Society of Gene and Cell Therapy Congress in Sevill ...